WO1996023522A1 - Treatment of diabetic neuropathy - Google Patents
Treatment of diabetic neuropathy Download PDFInfo
- Publication number
- WO1996023522A1 WO1996023522A1 PCT/AU1996/000046 AU9600046W WO9623522A1 WO 1996023522 A1 WO1996023522 A1 WO 1996023522A1 AU 9600046 W AU9600046 W AU 9600046W WO 9623522 A1 WO9623522 A1 WO 9623522A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- insulin
- treatment
- cream
- neuropathy
- diabetic neuropathy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Definitions
- This invention relates to the treatment of diabetic neuropathy, and in particular it relates to a novel method and composition for the topical treatment of this condition.
- Diabetic neuropathy also known as diabetic neuritis
- diabetic neuritis is a painful condition suffered by many diabetic patients, and arises from nerve dysfunction particularly at the extremities of the body such as the toes and feet.
- Table 1 outlines the Classification and Staging of Diabetic Neuropathy, based on the recommendations 1 of the American Diabetes Association, 1988.
- the first of two main pathological disturbances of normal nerve function in diabetes involves a postulated relationship between raised blood glucose levels (hyperglycaemia), the polyol pathway (the biochemical pathway triggered by high glucose levels and producing alcohol-sugars called polyols as the end-products), myo-inositol (a cell energy-storage substrate), Na7K + ATPase (ion-pump enzyme) activity and nerve conduction, that is, the speed of nerve impulse transmission (Greene et al. 2 ).
- the second postulated patho-physiological mechanism of disturbance of normal nerve function in diabetes relates to lack of oxygen within the nerve fibres, which is chemically-induced by raised blood sugar levels and activation of the polyol pathway, leading to changes in blood flow through micro-vessels within the nerves (Williamson et al. 3 ). TABLE 1 Classification and staging of diabetic neuropathy 1 (based on recommendations of the American Diabetes Association, 1988).
- Autonomic neuropathy a. abnormal pupillary function, b. sudomotor dysfunction, c. genitourinary autonomic neuropathy, i bladder dysfunction ii sexual dysfunction d. gastrointestinal autonomic neuropathy i gastric atony ii gall bladder atony iii diabetic diarrhoea e. cardiovascular autonomic neuropathy f. hypoglycaemic unawareness.
- Physical therapies applied to the affected painful region may sometimes provide symptomatic relief, e.g. i electrical stimulation such as TENS, interferential, vibration, ultrasound ii massage and rubbing iii hydrotherapy iv application of warmth, heat or cold v acupuncture or acupressure vi application of Opsite dressing film 11,12 .
- i electrical stimulation such as TENS, interferential, vibration, ultrasound ii massage and rubbing iii hydrotherapy iv application of warmth, heat or cold v acupuncture or acupressure vi application of Opsite dressing film 11,12 .
- Drugs and medications to be taken by mouth for pain relief include i non-steroidal analgesics (e.g. aspirin, paracetamol, ibuprofen, ketoprofen, etc.); ii narcotics, e.g codeine, morphine, pethidine, and sustained release morphine preparations; iii antidepressants including tricyclics such as amrtryptilline, etc.; iv anticonvulsants with inhibitory effects on relay of pain signals, such as carbamazepine, clonazepam; v antiarrhythmic compounds which reduce electrical excitability of cells such as mexilitene, lignocaine; vi aldose reductase inhibitors, such as Sorbinil, ponalrestat (ICI), epalrestat (Ono), tolrestat (Wyeth-Ayerst), zopolrestat (Pfizer) which may improve the levels of intraneural energy substrate
- GLA gamma-linolenic acid
- Topical treatments to desensitise superficial nerve fibres conveying pain signals, e.g. i capsaicin cream or ointment (usually as 0.025% or 0.075%) which is a neurotoxin and has been used for post-herpetic neuralgia 15,16,17 , and for painful diabetic neuropathy 18 .
- ii aspirin in vanishing cream or sorbolene has been reported by Kassirer 19 to relieve post-herpetic neuralgia, and has been used by the present inventors (Westerman and Zimmet, unpublished) and found to be sometimes effective in the burning painful diabetic neuropathy.
- Topical insulin therapy has not been reported previously, particularly in treatment of diabetic neuropathy. ln 1980, Snyder & Kim 20 made the first suggestion that insulin may be a nerve survival factor. Soon after, Low et a/. 4 described the reduced responses to sudomotor axon reflex tests as a small fibre dysfunction in neuropathy, and electrically evoked axon reflex responses were found to be reduced in diabetes mellitus 7 , and largely restored by a single dose of insulin in rat experimental STZ-diabetes 21 .
- transdermal iontophoresis in dermatology 25 has been shown to be effective in facilitating transport of peptides 26 , including insulin 2728 .
- the present inventor has conducted studies of the short-term effects of insulin on small nerve and axon reflex function in both animal studies in streptozotocin- induced diabetic rats and insulin-dependent diabetic patients 29 .
- the size of the skin flushing response to noxious stimulation was significantly reduced, although responses of small blood vessels themselves were not reduced. This indicates that the reduced inflammation was due to sensory nerve dysfunction rather than microvascular impairment.
- iontophoresis Topical application of insulin by six minutes of cathodal electrical current, termed iontophoresis, resulted in highly significant restoration of the size of the axon reflex, both in humans with IDDM and in rats made diabetic chemically with streptozotocin.
- the immediate restorative effect of the insulin iontophoresis indicates that the decline in the axon reflex is reversible, and therefore due to functional changes in the nerves mediating the response, rather than any structural defects.
- Mechanisms by which insulin produces these acute effects on nerves are now known, but the rapid time- course of the effect (in minutes) suggests some ionic or excitability changes, such as calcium levels within the nerves based on other indirect evidence of such actions of insulin 30,31 .
- the present invention provides the topical use of insulin in the treatment of diabetic neuropathy in a patient.
- the present invention provides a method for the treatment of diabetic neuropathy in a patient which comprises the topical administration of a therapeutically effective amount of insulin to the affected area of skin of the patient.
- the present invention provides a composition for the treatment of diabetic neuropathy in a patient, which comprises a therapeutically effective amount of insulin in a topical, pharmaceutically acceptable diluent or carrier.
- the present invention provides the use of a therapeutically effective amount of insulin in the manufacture of a medicament for topical use in the treatment of diabetic neuropathy in a patient.
- the insulin used in accordance with this invention is human insulin (available, for example, as Humulin R, Velosulin or Actrapid). It is to be understood, however, that the present invention also extends to the use of porcine insulin, bovine insulin or insulin from other non-human animal species.
- insulin as used herein is intended to encompass not only insulin per se, but also the a- or 7-subchains of insulin, separately or in combination.
- the insulin is administered in therapeutically effective amounts.
- a therapeutically effective amount means that amount necessary at least partly to attain the desired effect, or to delay the onset of, inhibit the progression of, or halt altogether, the onset or progression of the diabetic neuropathy condition being treated. Such amounts will depend, of course, on the particular condition being treated, the severity of the condition and individual patient parameters including age, physical condition, size, weight and other concurrent treatment. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation. It is preferred generally that a minimum effective dose be used according to sound medical judgement. It will be understood by those of ordinary skill in the art, however, that a higher dose may be administered for medical reasons, psychological reasons or for virtually any other reasons.
- Suitable pharmaceutically acceptable carriers and/or diluents include any and all conventional solvents, dispersion media, fillers, aqueous solutions, antibacterial and antifungal agents, absorption promoting agents, and the like.
- the use of such media and agents for pharmaceutically active substances is well known in the art, and it is described, by way of example, in Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Company, Pennsylvania, USA. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the pharmaceutical compositions of the present invention is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
- the topical preparations contemplated by the present invention include aqueous cream, ointment, gel, lotion, roll-on liquid, spray, glass bead wound dressing, synthetic polymer dressing impregnated with insulin, or any other method of transdermal application of insulin.
- the cream will include buffering agents and hydrophobic ingredients.
- These preparations may also include the use of compounds such as DMSO (dimethylsulfoxime) which would facilitate the passage of insulin across the skin keratin barrier and into epidermis.
- Topical Insulin Cream 70g of vanishing cream base (such as Home Brand skin repair cream, Sorbolene cream, or Cetomacrogol cream) containing purified water, stearic acid, dimethicone, isopropyl myristate, cetyl alcohol, triethanolamine, polysorbate 80, aloe vera extract, methyl paraben, propyl paraben, fragrance.
- vanishing cream base such as Home Brand skin repair cream, Sorbolene cream, or Cetomacrogol cream
- vanishing cream base such as Home Brand skin repair cream, Sorbolene cream, or Cetomacrogol cream
- purified water stearic acid, dimethicone, isopropyl myristate, cetyl alcohol, triethanolamine, polysorbate 80, aloe vera extract, methyl paraben, propyl paraben, fragrance.
- Sorbolene lotion contains de-ionised water, glycerine, sorbitol, light mineral oil, cetyl alcohol, cetomacrogol 1000, stearic acid, triethanolamine, tocopheryl acetate, imidazolidinyl urea, methyl paraben, EDTA, para-cresol.
- Sorbolene lotion contains de-ionised water, glycerine, sorbitol, light mineral oil, cetyl alcohol, cetomacrogol 1000, stearic acid, triethanolamine, tocopheryl acetate, imidazolidinyl urea, methyl paraben, EDTA, para-cresol.
- the topical preparation of this invention is applied at least daily, or several times daily, to the affected area of the skin of the patient.
- the application may be applied twice daily (morning and night), or even three times daily.
- Effective treatment begins with careful selection of suitable patients having diabetic neuropathy and symptoms associated with small fibre dysfunction.
- the clinical picture for which the topical insulin treatment is most appropriate and most likely to benefit is that particular neuropathy symptom- complex involving superficial burning type of discomfort with dysesthesia or paraesthesia (Pfeifer et a/. 9,10 ). Patients with non-insulin dependent diabetes and not previously insulin-treated are most suitable.
- the topical insulin cream is applied at twice daily frequency restricted to skin areas with superficial burning discomfort. This is most commonly the toes, feet and lower parts of legs.
- Re-measurement of thermal perception thresholds on treated skin zones at monthly intervals is performed according to the methods described by Jamal et a/. 323334 and Delaney et a/. 824 using the Medelec TTT device. Both cold and warm perception thresholds are measured.
- thermal perception threshold which may be interpreted as an improved thermal sensory acuity. This may be related to an improved sensory nerve function. Cold threshold improves more rapidly than warm threshold, suggesting greater benefit for the myelinated A-delta nerve fibres mediating cold sensation.
- Preferred aspects of the topical use of insulin in the treatment of diabetic neuropathy include the following:
- the insulin concentration in a cream may range from 0.01-20 IU per gram, preferably 0.1-10 IU per gram, more preferably 1-3 IU per gram.
- the amount of cream applied is usually about 0.5g on each foot/leg. The consistency of the preferred cream tends to be a little sloppy, and it is therefore easily spread and rubbed into the skin until it has vanished.
- the recommended application frequency is twice to thrice daily, but after longer-term trials, a lesser frequency such as once daily might be acceptable for maintenance therapy or skin ulcer prophylaxis.
- Symptomatic patients particularly those with type 2 (non-insulin- dependent) diabetes mellitus most suitable for treatment with topical insulin cream are identified after a careful history of symptoms (see Pfeifer algorithm 910 ) and testing for neuropathy with a group of investigations. These include testing small sensory nerve function by pinprick and cotton-wool sensibility, and warm and cold perception thresholds at wrist and foot dorsum, and AC-current perception thresholds
- Body weight, height, body mass index (BMI), abdominial circumference, fasting plasma glucose and insulin and haemoglobin A ⁇ are also measured to provide an indication of insulin sensitivity in type 2 subjects and quality of glycemic control in both type 1 and 2 subjects.
- Euglycemic clamp measurements have not yet been used in these studies for logistic reasons.
- Suitable topical vehicles for use in administration of insulin accordance with this invention, and methods of preparation thereof, include the following:
- Figures 1 to 3 show graphically the results of topical insulin treatment of painful burning feet in cases of diabetic neuropathy selected according to the criteria previously described (see page 10, paras, iv, v and Pfeifer 9,10 ).
- Topical insulin cream of the composition described above (1 IU insulin per gram of finished cream) was provided to the patients, with instructions to apply about 0.5g on each foot/leg two or three times daily.
- Figures 1 and 2 relate to a maximum number of 30 Type 2 diabetic subjects who had not been treated with systemic insulin.
- Figure 3 depicts the results from a maximum of 16 subjects who had received systemic insulin treatment.
- the vertical axis depicts the thermal threshold: open rectangles being the warm perception threshold, black filled rectangles being the cold threshold.
- the severity of the painful burning symptoms on a 10 point visual analogue scale is also shown on the vertical axis by the filled black circles.
- the horizontal axis shows the duration of treatment at which the tests and re-tests were performed.
- the horizontal dotted line shows the upper limit of the normal 95% confidence margin (mean + 2.2 standard deviations).
- Figure 1 shows the results from 12 weeks treatment, the number of subjects being 30 for weeks 0 and 4 and decreasing progressively to 16 at week
- FIG. 2 graph shows on a time scale of months the same trends, and it will be noted that warm threshold has become significantly improved (i.e. WPT reduced) by 4 months of treatment.
- Figure 3 shows the results of treatment of a smaller group of patients who had received systemic insulin treatment. These include some patients with Type 2 DM, whose deterioration ultimately required systemic insulin treatment; the remainder include patients with Type 1 DM.
- the lack of improvement in thermal threshold results for warm and cold in this group contrasts markedly with those from the previous group, but also surprising is the symptomatic improvement noted by these patients.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8523119A JPH11502513A (ja) | 1995-02-02 | 1996-02-01 | 糖尿病性ニューロパシーの処置方法 |
EP96901190A EP0808170A1 (en) | 1995-02-02 | 1996-02-01 | Treatment of diabetic neuropathy |
KR1019970705293A KR19980701896A (ko) | 1995-02-02 | 1996-02-01 | 당뇨병 환자의 신경장애 치료 |
AU45315/96A AU4531596A (en) | 1995-02-02 | 1996-02-01 | Treatment of diabetic neuropathy |
NO973548A NO973548L (no) | 1995-02-02 | 1997-08-01 | Behandling av diabetisk neuropati |
FI973216A FI973216A (fi) | 1995-02-02 | 1997-08-04 | Diabeettisen neuropatian hoito |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPN0892A AUPN089295A0 (en) | 1995-02-02 | 1995-02-02 | Treatment of diabetic neuropathy |
AUPN0892 | 1995-02-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996023522A1 true WO1996023522A1 (en) | 1996-08-08 |
Family
ID=3785252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU1996/000046 WO1996023522A1 (en) | 1995-02-02 | 1996-02-01 | Treatment of diabetic neuropathy |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0808170A1 (fi) |
JP (1) | JPH11502513A (fi) |
KR (1) | KR19980701896A (fi) |
AU (1) | AUPN089295A0 (fi) |
CA (1) | CA2211450A1 (fi) |
FI (1) | FI973216A (fi) |
NO (1) | NO973548L (fi) |
WO (1) | WO1996023522A1 (fi) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998024470A1 (en) * | 1996-12-03 | 1998-06-11 | Dardai Zoltan | Topical preparation for introducing peptidaceous pharmacons in living organisms |
EP1383540A2 (en) * | 2000-07-31 | 2004-01-28 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
US7638484B2 (en) | 2003-08-07 | 2009-12-29 | Healor Ltd. | Methods for accelerating wound healing by administration of adipokines |
US8093211B2 (en) | 2000-07-31 | 2012-01-10 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
EP2646046A2 (en) * | 2010-11-30 | 2013-10-09 | Joslin Diabetes Center, Inc. | Compositions and methods for the treatment of nervous disorders associated with diabetes |
US9545487B2 (en) | 2012-04-13 | 2017-01-17 | Boehringer Ingelheim International Gmbh | Dispenser with encoding means |
US9682202B2 (en) | 2009-05-18 | 2017-06-20 | Boehringer Ingelheim International Gmbh | Adapter, inhalation device, and atomizer |
US9724482B2 (en) | 2009-11-25 | 2017-08-08 | Boehringer Ingelheim International Gmbh | Nebulizer |
US9744313B2 (en) | 2013-08-09 | 2017-08-29 | Boehringer Ingelheim International Gmbh | Nebulizer |
US9757750B2 (en) | 2011-04-01 | 2017-09-12 | Boehringer Ingelheim International Gmbh | Medicinal device with container |
US9827384B2 (en) | 2011-05-23 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Nebulizer |
US9943654B2 (en) | 2010-06-24 | 2018-04-17 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10004857B2 (en) | 2013-08-09 | 2018-06-26 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10011906B2 (en) | 2009-03-31 | 2018-07-03 | Beohringer Ingelheim International Gmbh | Method for coating a surface of a component |
US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10099022B2 (en) | 2014-05-07 | 2018-10-16 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10124125B2 (en) | 2009-11-25 | 2018-11-13 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10124129B2 (en) | 2008-01-02 | 2018-11-13 | Boehringer Ingelheim International Gmbh | Dispensing device, storage device and method for dispensing a formulation |
US10195374B2 (en) | 2014-05-07 | 2019-02-05 | Boehringer Ingelheim International Gmbh | Container, nebulizer and use |
US10722666B2 (en) | 2014-05-07 | 2020-07-28 | Boehringer Ingelheim International Gmbh | Nebulizer with axially movable and lockable container and indicator |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4136685A (en) * | 1984-04-18 | 1985-10-24 | Geriaco A.G. | Product for the treatment of acne vulgaris |
AU4292585A (en) * | 1984-04-30 | 1985-11-28 | Trustees Of Columbia University In The City Of New York, The | Topical treatment of diabetes with insulin and penetrant enhancer applied to the skin and covered by a patch |
DD254881A1 (de) * | 1986-10-29 | 1988-03-16 | Univ Dresden Tech | Nicht parenteral anwendbares insulinpraeparat mit verzoegerter wirkung |
JPH04149126A (ja) * | 1990-10-09 | 1992-05-22 | Mitsubishi Kasei Corp | 経粘膜投与用医薬組成物 |
US5145679A (en) * | 1989-10-05 | 1992-09-08 | Hinson Joan B | Topical emollient for prevention and treatment of circulatory induced lesions |
EP0561330A1 (de) * | 1992-03-17 | 1993-09-22 | Pharmed Dr. Liedtke Gmbh | Topische Arzneiformen mit Insulin |
FR2710529A1 (fr) * | 1993-09-29 | 1995-04-07 | Zirinis Phedon | Gel aqueux à usage nasal, pellets, et leur procédé de préparation. |
FR2710530A1 (fr) * | 1993-09-29 | 1995-04-07 | Zirinis Phedon | Gel aqueux à usage nasal, pellets, et leur procédé de préparation. |
-
1995
- 1995-02-02 AU AUPN0892A patent/AUPN089295A0/en not_active Abandoned
-
1996
- 1996-02-01 WO PCT/AU1996/000046 patent/WO1996023522A1/en not_active Application Discontinuation
- 1996-02-01 JP JP8523119A patent/JPH11502513A/ja active Pending
- 1996-02-01 EP EP96901190A patent/EP0808170A1/en not_active Withdrawn
- 1996-02-01 KR KR1019970705293A patent/KR19980701896A/ko not_active Application Discontinuation
- 1996-02-01 CA CA002211450A patent/CA2211450A1/en not_active Abandoned
-
1997
- 1997-08-01 NO NO973548A patent/NO973548L/no unknown
- 1997-08-04 FI FI973216A patent/FI973216A/fi unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4136685A (en) * | 1984-04-18 | 1985-10-24 | Geriaco A.G. | Product for the treatment of acne vulgaris |
AU4292585A (en) * | 1984-04-30 | 1985-11-28 | Trustees Of Columbia University In The City Of New York, The | Topical treatment of diabetes with insulin and penetrant enhancer applied to the skin and covered by a patch |
DD254881A1 (de) * | 1986-10-29 | 1988-03-16 | Univ Dresden Tech | Nicht parenteral anwendbares insulinpraeparat mit verzoegerter wirkung |
US5145679A (en) * | 1989-10-05 | 1992-09-08 | Hinson Joan B | Topical emollient for prevention and treatment of circulatory induced lesions |
JPH04149126A (ja) * | 1990-10-09 | 1992-05-22 | Mitsubishi Kasei Corp | 経粘膜投与用医薬組成物 |
EP0561330A1 (de) * | 1992-03-17 | 1993-09-22 | Pharmed Dr. Liedtke Gmbh | Topische Arzneiformen mit Insulin |
FR2710529A1 (fr) * | 1993-09-29 | 1995-04-07 | Zirinis Phedon | Gel aqueux à usage nasal, pellets, et leur procédé de préparation. |
FR2710530A1 (fr) * | 1993-09-29 | 1995-04-07 | Zirinis Phedon | Gel aqueux à usage nasal, pellets, et leur procédé de préparation. |
Non-Patent Citations (16)
Title |
---|
ANN. ACAD. MED. SILES., Volume 20, (1990), RYSZKA F. and GALOCH B., "Pharmaceutical Availability of Insulin from Ointment", pages 39-43. * |
ANN. ACAD. MED. SILES., Volume 25, (1992), RYSZKA F. and TATOMIR-SZMYT I., "Influence of Selected Tensides on Insulin Release from Ointment", pages 37-40. * |
BOLL. CHIM. FARMACEUTICO, Volume 132, No. 6, (1993), RYSZKA F. et al., "The Release of 125I-Labelled Insulin from Ointment In Vitro and In Vivo", pages 197-200. * |
DIABETES RESEARCH, Volume 8, No. 2, (1988), DUNLOP M.E. et al., "The Influence of Insulin and Sorbinil on Myoinositol Uptake in Peripheral Nerve from Normal and Diabetic Rats and a Neuroblastoma Cell Line (NTE-115)", pages 51-57. * |
INDIAN J. PHARM. SCI., Volume 56(6), (1994), CHANDRASHEKAR G. et al., "Optimization of Parameters for Transdermal Permeation of Insulin", pages 205-209. * |
INTERNATIONAL JOURNAL OF PHARMACEUTICS, Volume 83, (1992), RYDEN L. and EDMAN P., "Effect of Polymers and Microspheres on the Nasal Absorption of Insulin in Rats", pages 1-10. * |
INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE, Volume 32, No. 12, (1991), PILLION D.J. et al., "Systemic Absorption of Insulin Delivered Topically to the Rat Eye", pages 3021-3027. * |
J. PHARM. PHARMACOL., Volume 46, (1994), NOMURA M. et al., "Effect of Addition of Hyaluronic Acid to Highly Concentrated Insulin on Absorption from the Conjunctiva in Conscious Diabetic Dogs", pages 768-770. * |
JOURNAL OF OCULAR PHARMACOLOGY, Volume 10, No. 1, (1994), BARTLETT J.D. et al., "Toxicity of Insulin Administered Chronically to Human Eye in Vivo", pages 101-107. * |
NEUROSCI. LETT., Volume 129, No. 1, (1991), SOTELO J.R. et al., "An in Vitro Model to Study Diabetic Neuropathy", pages 91-94. * |
PATENT ABSTRACTS OF JAPAN, Vol. 112C, 983; & JP,A,04 149 126 (MITSUBISHI KASEI CORP.), Published 22 May 1992. * |
PHARMACEUTICAL RESEARCH, Volume 9, No. 6, (1992), HAYAKAWA E. et al., "Conjunctival Penetration of Insulin and Peptide Drugs in Albino Rabbit", pages 769-775. * |
SURGICAL FORUM, (1984), KAZIM M. et al., "Effect of Topical Insulin on Blood Glucose of Diabetic Mice", pages 64-67. * |
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, Volume 249, No. 1, (1989), YAMAMOTO A. et al., "The Ocular Route of Systemic Insulin Delivery in the Albino Rabbit", pages 249-255. * |
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, Volume 271, No. 3, (1994), PILLION D.J. et al., "Alkylglycosides Enhance Systemic Absorption of Insulin Applied Topically to the Rat Eye", pages 1274-1280. * |
YAKUGAKU ZASSHI, Volume 113, No. 5, (1993), MACHIDA Y., "Development of Topical Drug Delivery Systems Utilizing Polymeric Materials", pages 356-368. * |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998024470A1 (en) * | 1996-12-03 | 1998-06-11 | Dardai Zoltan | Topical preparation for introducing peptidaceous pharmacons in living organisms |
AU744380B2 (en) * | 1996-12-03 | 2002-02-21 | Diabetic Trust Ag | Topical preparation for introducing peptidaceous pharmacons in living organisms |
AP1065A (en) * | 1996-12-03 | 2002-04-30 | Diabetic Trust Ag | Topical preparation for introducing peptidaceous pharmacons in living organisms. |
US6399566B1 (en) | 1996-12-03 | 2002-06-04 | Diabetictrust Ag | Topical preparation for introducing insulin in living organisms |
US8093211B2 (en) | 2000-07-31 | 2012-01-10 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
EP1383540A4 (en) * | 2000-07-31 | 2004-06-30 | Univ Bar Ilan | PHARMACEUTICAL METHODS AND COMPOSITIONS FOR HEALING LESIONS |
US7402571B2 (en) | 2000-07-31 | 2008-07-22 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
EP1383540A2 (en) * | 2000-07-31 | 2004-01-28 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
US7638484B2 (en) | 2003-08-07 | 2009-12-29 | Healor Ltd. | Methods for accelerating wound healing by administration of adipokines |
US10124129B2 (en) | 2008-01-02 | 2018-11-13 | Boehringer Ingelheim International Gmbh | Dispensing device, storage device and method for dispensing a formulation |
US10011906B2 (en) | 2009-03-31 | 2018-07-03 | Beohringer Ingelheim International Gmbh | Method for coating a surface of a component |
US9682202B2 (en) | 2009-05-18 | 2017-06-20 | Boehringer Ingelheim International Gmbh | Adapter, inhalation device, and atomizer |
US10124125B2 (en) | 2009-11-25 | 2018-11-13 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
US9724482B2 (en) | 2009-11-25 | 2017-08-08 | Boehringer Ingelheim International Gmbh | Nebulizer |
US9943654B2 (en) | 2010-06-24 | 2018-04-17 | Boehringer Ingelheim International Gmbh | Nebulizer |
EP2646046A4 (en) * | 2010-11-30 | 2015-03-18 | Joslin Diabetes Center Inc | COMPOSITIONS AND METHODS FOR TREATING NERVOUS DISORDER IN CONNECTION WITH DIABETES |
EP2646046A2 (en) * | 2010-11-30 | 2013-10-09 | Joslin Diabetes Center, Inc. | Compositions and methods for the treatment of nervous disorders associated with diabetes |
US9757750B2 (en) | 2011-04-01 | 2017-09-12 | Boehringer Ingelheim International Gmbh | Medicinal device with container |
US9827384B2 (en) | 2011-05-23 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10220163B2 (en) | 2012-04-13 | 2019-03-05 | Boehringer Ingelheim International Gmbh | Nebuliser with coding means |
US9545487B2 (en) | 2012-04-13 | 2017-01-17 | Boehringer Ingelheim International Gmbh | Dispenser with encoding means |
US9744313B2 (en) | 2013-08-09 | 2017-08-29 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10004857B2 (en) | 2013-08-09 | 2018-06-26 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10894134B2 (en) | 2013-08-09 | 2021-01-19 | Boehringer Ingelheim International Gmbh | Nebulizer |
US11642476B2 (en) | 2013-08-09 | 2023-05-09 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10716905B2 (en) | 2014-02-23 | 2020-07-21 | Boehringer Lngelheim International Gmbh | Container, nebulizer and use |
US10099022B2 (en) | 2014-05-07 | 2018-10-16 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10195374B2 (en) | 2014-05-07 | 2019-02-05 | Boehringer Ingelheim International Gmbh | Container, nebulizer and use |
US10722666B2 (en) | 2014-05-07 | 2020-07-28 | Boehringer Ingelheim International Gmbh | Nebulizer with axially movable and lockable container and indicator |
Also Published As
Publication number | Publication date |
---|---|
FI973216A0 (fi) | 1997-08-04 |
NO973548D0 (no) | 1997-08-01 |
JPH11502513A (ja) | 1999-03-02 |
CA2211450A1 (en) | 1996-08-08 |
EP0808170A1 (en) | 1997-11-26 |
FI973216A (fi) | 1997-10-01 |
NO973548L (no) | 1997-10-02 |
AUPN089295A0 (en) | 1995-03-02 |
KR19980701896A (ko) | 1998-06-25 |
MX9705920A (es) | 1998-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0808170A1 (en) | Treatment of diabetic neuropathy | |
Poyer et al. | Prostaglandin F2 alpha effects on isolated rhesus monkey ciliary muscle. | |
US5411738A (en) | Method for treating nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine | |
Rowbotham et al. | Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia | |
Rowbotham et al. | Topical lidocaine reduces pain in post-herpetic neuralgia | |
US6670395B1 (en) | Prophylactic and therapeutic treatment of skin sensitization and irritation | |
Toris et al. | Potential mechanism for the additivity of pilocarpine and latanoprost | |
AU2310200A (en) | Pharmaceutical compositions | |
JP2002515401A5 (fi) | ||
KR950015056B1 (ko) | 통증을 수반하는 염증성 또는 알레르기성 질환치료에 사용되는 의약조성물 | |
WO2004091498A2 (en) | Alcohol-free transdermal insulin composition and processes for manufacture and use thereof | |
CA2001797A1 (en) | Topical ointment for dermatosis | |
US20030181515A1 (en) | Methods of using kavalactone compositions | |
JPH08505388A (ja) | ヒアルロン酸−尿素医薬組成物およびその使用 | |
Weinreb et al. | A double-masked three-month comparison between 0.25% betaxolol suspension and 0.5% betaxolol ophthalmic solution | |
Malmros et al. | Plasma concentrations and analgesic effect of EMLA (lidocaine/prilocaine) cream for the cleansing of leg ulcers. | |
SG176679A1 (en) | Treatment of eye discomfort by topical administration of a cooling agent to the external surface of the eyelid | |
US20200360317A1 (en) | Carboxylic acids for treating/preventing a skin disease | |
Freeman et al. | Topical anaesthesia of the skin: a review | |
Nishihata et al. | Clinical investigation of sodium diclofenac sustained-release suppositories | |
MXPA97005920A (en) | Treatment of neuropathy diabet | |
US20190160030A1 (en) | Carboxylic acids for early childhood application | |
US20220062308A1 (en) | Methods and compositions for treating rosacea | |
Levin et al. | Treatment of irritant contact dermatitis | |
Jacob | DMSO: potential usefulness in physical therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96192272.9 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AZ BY KG KZ RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2211450 Country of ref document: CA Ref document number: 2211450 Country of ref document: CA Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 1996 523119 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1997/005920 Country of ref document: MX Ref document number: 300542 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970705293 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 973216 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996901190 Country of ref document: EP |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWP | Wipo information: published in national office |
Ref document number: 1996901190 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970705293 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996901190 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1019970705293 Country of ref document: KR |